New meta-analysis below [1] [2].
I remember a significant study where brachy boost reduced PCa mortality but not overall mortality, so I would be wary of it. However, some feel that reducing PCa death is worthwhile even if it does increase the risk of death from other causes.
"In men with localized prostate cancer, the addition of androgen-deprivation therapy (ADT) or a brachytherapy boost (BT) to external beam radiotherapy (EBRT) have been shown to improve various oncologic end points. Practice patterns indicate that those who receive BT are significantly less likely to receive ADT, and thus we sought to perform a network meta-analysis to compare the predicted outcomes of a randomized trial of EBRT plus ADT versus EBRT plus BT."
"The results showed that adding ADT to EBRT significantly improved OS {overall survival} versus EBRT alone (hazard ratio [HR] 0.70 ...). Separate analyses of trials that enrolled mostly men with high-risk disease versus those with intermediate-risk disease yielded similar results (HR 0.66 ... for high risk; HR 0.73 ... for intermediate risk).
"In contrast, the addition of BT to EBRT (with or without ADT) did not improve OS "
-Patrick